Abstract
The presence of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurities in angiotensin II receptor blocker (ARB) drugs containing tetrazole ring has triggered worldwide product recalls. The purpose of this article is to identify the potential gap area in current pharmaceutical industry practice that might have led to the NMDA and NDEA impurities escaping the drug manufacturer’s and FDA’s attention. The impact of process change was not adequately assessed by the manufacturer of contaminated APIs (active pharmaceutical ingredients), and potential for generation of mutagenic or other toxic impurities was not considered. The safety and risk associated with a chemical synthetic process was also not evaluated. This is primarily due to current industry practice which focuses on controlling the impurities above reporting threshold. ICH Q3A and FDA guidance on genotoxic and carcinogenic impurities in drug substances and products need to be integrated so that the ICH Q3A decision tree (attachment 3) begins by checking whether the synthetic process has been evaluated for the potential to generate toxic impurities. The compliance with ICH Q3A limits should be carried out only after the process has been determined to be safe without the risk of generating mutagenic and carcinogenic impurities.
Similar content being viewed by others
References
FDA (2019) FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. Accessed 21 Jan 2019. https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm.
EMA (2018) EU authorities take further action in ongoing review of sartans: Zheijiang Huahai placed under increased supervision; Aurobindo Pharma stopped from supplying irbesartan to the EU. Accessed 21 Jan 2019. https://www.ema.europa.eu/en/news/eu-authorities-take-further-action-ongoing-review-sartans-zheijiang-huahai-placed-under-increased#_ftn1
Shanley A. After Valsartan Recalls, Regulators grapple with nitrosamine contamination in APIs. Pharma Tech 2018. Accessed 21 Jan 2019. http://www.pharmtech.com/after-valsartan-recalls-regulators-grapple-nitrosamine-contamination-apis
EMA (2018b) Press release on 13th September. Update on review of valsartan medicines: risk from NDMA remains low, a related substance NDEA also being investigated. Accessed 21 Jan 2019. https://www.ema.europa.eu/en/news/update-review-valsartan-medicines-risk-ndma-remains-low-related-substance-ndea-also-being
Pottegard A, Kristensen K, Ernst MT, Johansen NB, Quartorolo P, Hallas J. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. Br Med J. 2018;362:k3851.
IARC (1978) Some N-nitroso Compounds: IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. International Agency for Research on Cancer, Lyon, France.
González CA, Riboli E, Badosa J, Batiste E, Cardona T, Pita S, et al. Nutritional factors and gastric cancer in Spain. Am J Epidemiol. 1994;139:466–73.
La Vecchia C, D’Avanzo B, Airoldi L, Braga C, Decarli A. Nitrosamine intake and gastric cancer. Eur J Cancer Prev. 1995;4:469–74.
Pobel D, Riboli E, Cornée J, Hémon B, Guyader M. Nitrosamine, nitrate and nitrite in relation to gastric cancer: a case–control study in Marseille, France. Eur J Epidemiol. 1995;11:67–73.
Goodman MT, Hankin JH, Wilkens LR, Kolonel LN. High fat foods and the risk of lung cancer. Epidemiology. 1992;3:288–99.
De Stefani E, Deneo-Pellegrini H, Carzoglio JC, Ronco A, Mendilaharsu M. Dietary nitrosodimethylamine and the risk of lung cancer: a case–control study from Uruguay. Cancer Epidemiol Biomarkers Prev. 1196(5):679–82.
Knekt P, Järvinen R, Dich J, Hakulinen T. Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: a follow-up study. Int J Cancer. 1999;80:852–6.
Archer MC. Mechanisms of action of N-nitroso compounds. Cancer Surv. 1989;2:241–50.
Nakae D, Kobayashi Y, Akai H. Involvement of 8-hydroxyguanine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res. 1997;57(7):1281–7.
Dragan YP, Hully JR, Nakamura J, Mass MJ, Swenberg JA, Pitot HC. Biochemical events during initiation of rat hepatocarcinogenesis. Carcinogenesis. 1994;15(7):1451–8.
EPA Integrated Risk Information System (IRIS). “N-nitrosodimethylamine; CASRN 1993; 62–75-9.” https://cfpub.epa.gov/ncea/iris/iris_documents/documents/subst/0045_summary.pdf Accessed 21 Jan 2019.
WHO (2008). N-nitrosodimethylamine in drinking-water. Background document for preparation of WHO Guidelines for drinking-water quality. Geneva, World Health Organization (WHO/HSE/AMR/08.03/8). Accessed 21 Jan 2019. https://www.who.int/water_sanitation_health/dwq/chemicals/ndmasummary_2ndadd.pdf
FDA (1996) FDA compliance policy guides manual: sec. 510.600 dimethylnitrosamine in malt beverages. US Food and Drug Administration, Washington, DC.
FDA (1995) FDA compliance policy guides manual: sec. 578.500 dimethylnitrosamine in barley malt. US Food and Drug Administration, Washington, DC.
ICH (2006) IMPURITIES IN NEW DRUG SUBSTANCES Q3A(R2). Accessed 21 Jan 2019. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf
Krasner SW, Mitch WA, McCurry DL, Hanigan D, Westerhoff P. Formation, precursors, control, and occurrence of nitrosamines in drinking water: a review. Water Res. 2013;47(13):4433–50.
Mitch WA, Sedlak DL. Characterization and fate of N-nitrosodimethylamine precursors in municipal wastewater treatment plants. Environ Sci Technol. 2004;38(5):1445–54.
FDA (2008) Genotoxic and carcinogenic impurities in drug substances and products: recommended approaches. Draft guidance. Accessed 21 Jan 2019. http://www.triphasepharmasolutions.com/Resources/Guidance%20for%20Industry%20Genotoxic%20Agents.pdf
EMA (2006) Guideline on the limits of genotoxic impurities. Accessed on Jan 21, 2019. https://www.ema.europa.eu/documents/scientific-guideline/guideline-limits-genotoxic-impurities_en.pdf
FDA (2019) Combined N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurity assay by GC/MS-headspace. Available at: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM623198.pdf (Accessed 6th March 2019).
EDQM (2018) OMCLs release three methods for determination of NDMA in sartans. Available at: https://www.edqm.eu/en/news/omcls-release-three-methods-determination-ndma-sartans . (Accessed 6 th March 2019).
Looker AR, Ryan MP, Neubert-Langille BJ, Naji R. Risk assessment of potentially genotoxic impurities within the framework of quality by design. Org Process Res Dev. 2010;14:1032–6.
Cimarosti Z, Bravo F, Stonestreet P, Tinazzi F, Vecchi O, Camurri G. Application of quality by design principles to support development of a control strategy for the control of genotoxic impurities in the manufacturing process of a drug substance. Org Process Res Dev. 2010;14:993–8.
Acknowledgements
This article reflects the scientific opinion of the authors and not necessarily the policies of the Zeino Pharma FZ LLC and Neopharma LLC.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guest Editors: Ajaz S. Hussain, Kenneth Morris, and Vadim J. Gurvich
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Charoo, N.A., Ali, A.A., Buha, S.K. et al. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities. AAPS PharmSciTech 20, 166 (2019). https://doi.org/10.1208/s12249-019-1376-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/s12249-019-1376-1